SPAQ-CO™/Supyra® (sulfadoxine-pyrimethamine + amodiaquine) for seasonal preventive treatment of malaria

Malaria is a major cause of childhood death across the sub-Sahel region in Africa. Most of the malaria morbidity occurs during the rainy season. Effective malaria chemoprevention during this period has been shown to prevent illness and death from malaria in children.1  

A preventive treatment for the malaria season 

Seasonal malaria chemoprevention (SMC) is defined as the intermittent administration of full treatment courses of an antimalarial medicine during the malaria season to prevent malarial illness by maintaining drug concentrations in the blood throughout the period of greatest transmission.1 

SMC prevents approximately 75% of all malaria episodes and approximately 75% of severe malaria episodes.1 The treatment may result in a decrease in child mortality of around 1 in 1,000. It also probably reduces the incidence of moderately severeanaemia. 

SPAQ: WHO’s recommended medicine for SMC  

In March 2012, WHO recommended SMC using a complete treatment of sulfadoxine-pyrimethamine and amodiaquine (SPAQ) once a month for 4 months during the malaria transmission season for children aged between 3 and 59 months. MMV has been supporting this recommendation and working to enhance the reach of this treatment to populations that need it.